reports
- ABGSC IT Research
- Øystein Elton Lodgaard
Change in number of shares and votes in HMS Networks
Change in number of shares and votes in HMS Networks As previously announced, HMS Networks has carried out a directed share issue. The directed share issue has resulted in a change in the number of shares and votes in HMS Networks. Prior to the directed share issue, the total number of shares in HMS Networks amounted to 46,818,868, corresponding to 46,818,868 votes. The number of shares and votes has as a result of the directed share issue increased by 3,500,000. As of April 30, 2024, the total number of shares in HMS Networks amounts to 50,318,868, corresponding to 50,318,868 votes.1 ...
Förändring av antalet aktier och röster i HMS Networks
Förändring av antalet aktier och röster i HMS Networks HMS Networks har som tidigare offentliggjorts genomfört en riktad nyemission av aktier. Emissionen har resulterat i en förändring av antalet aktier och röster i HMS Networks. Före emissionen fanns sammanlagt 46 818 868 aktier i HMS Networks, motsvarande 46 818 868 röster. Antalet aktier och röster har genom emissionen ökat med 3 500 000. Per den 30 april 2024 finns det sammanlagt 50 318 868 aktier i HMS Networks, motsvarande 50 318 868 röster.1 För mer information, vänligen kontakta:Staffan Dahlström, VD HMS, ...
- ABGSC IT Research
- Øystein Elton Lodgaard
Ultimovacs ASA: Invitation to first quarter 2024 results webcast prese...
Ultimovacs ASA: Invitation to first quarter 2024 results webcast presentation Oslo, April 30, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, invites to a webcast presentation of its first quarter 2024 results on Tuesday, May 7, 2024. The presentation can be followed as a live webcast accessed through a link on at 14:00 CET on Tuesday, May 7, 2024, and is scheduled to conclude at 14:55 CET. The webcast presentation will be available on the Ultimovacs website, and it will be possible to post questions duri...
HMS Networks AB: 1 director
A director at HMS Networks AB bought 625 shares at 400.000SEK and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
- Patrik Ling
Swedish Orphan Biovitrum (Buy, TP: SEK335.00) - Strong start to 2024
The Q1 earnings were above our forecast, even though some of the positive effects were one-offs (manufacturing revenues, among others). We believe Vonjo sales have bottomed out and we should be back at QOQ growth from Q2. The haemophilia franchise enjoyed stronger than expected growth, but some of this was due to phasing between quarters (hence this might hurt Q2 sales slightly). We reiterate our BUY and have increased our target price to SEK335 (320).
- ABGSC Healthcare Research
- Alexander Krämer
- Morten Larsen
- ABGSC IT Research
- Øystein Elton Lodgaard
- Johannes Grunselius
Stora Enso (Buy, TP: EUR16.50) - On track
Due to better volumes and prices in the packaging materials division, underlying Q1 earnings were above our expectations. Looking ahead, earnings are set to be supported by higher pulp prices at the same time as pricing power has strengthened for most of Stora Enso’s packaging products. We have made limited changes to our 2024–2027 forecasts, but as we are increasingly confident that Stora Enso will be able to raise its profits to a sustainably healthy level, we have increased our target price t...
- ABGSC Pulp & Paper Research
- Ali Shemmari
- Martin Melbye
- ABGSC Healthcare Research
- Alexander Krämer
- Morten Larsen
- ABGSC IT Research
- Øystein Elton Lodgaard
Ultimovacs Announces Poster Presentation at the 2024 American Society ...
Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting NON-REGULATORY PRESS RELEASE Oslo, April 24, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces that the data from the Phase II clinical trial INITIUM (), will be presented in a poster session at the 2024 ASCO Annual Meeting, taking place May 31 – June 4, 2024, in Chicago, IL & Online. INITIUM is an Ultimovacs-sponsored randomized, comparative, multi...
- ABGSC IT Research
- Øystein Elton Lodgaard
- ABGSC IT Research
- Øystein Elton Lodgaard
Resolutions at the Annual General Meeting in HMS Networks
Resolutions at the Annual General Meeting in HMS Networks HMS Networks AB (publ) held its Annual General Meeting on April 23, 2024. The Meeting resolved in favour of all matters in accordance with the proposals of the Board of Directors and the Nomination Committee. The main contents of the most important resolutions are described below. ALLOCATION OF EARNINGSThe Annual General Meeting resolved to approve the Board's proposed dividend of SEK 4.40 per share. The record date for the dividend was set to be April 25, 2024. The dividend is expected to be distributed by Euroclea...
Beslut vid årsstämman i HMS Networks
Beslut vid årsstämman i HMS Networks HMS Networks AB (publ) har den 23 april 2024 hållit årsstämma. I samtliga ärenden beslutade stämman i enlighet med styrelsens och valberedningens förslag. I det följande redogörs för de viktigaste beslutens huvudsakliga innehåll. VINSTDISPOSITIONÅrsstämman beslutade att bifalla styrelsens förslag om utdelning med 4,40 kr per aktie. Som avstämningsdag för utdelning fastslogs den 25 april 2024. Utdelning beräknas därmed att utsändas genom Euroclear Swedens försorg den 30 april 2024. FASTSTÄLLANDE AV RESULTAT- OCH BALANSRÄKNING OCH ANS...
Ultimovacs ASA – Annual General Meeting held on April 18, 2024
Ultimovacs ASA – Annual General Meeting held on April 18, 2024 Oslo, April 18, 2023: Ultimovacs ASA held its annual general meeting today April 18, 2024. All the matters on the agenda were approved. The following board members were re-elected for a period of one year, and the Board of Directors will consist of the following persons: Jónas Einarsson, Chair of the BoardHenrik Schüssler, board member Kari Grønås, board member Ketil Fjerdingen, deputy board member The Nomination Committee will consist of the following persons until the Annual General Meeting in 2025: Ole Kristian Hjelstue...
- Sean Conroy
Ultimovacs - Steadfast commitment to UV1 progression
Despite the recent setback with the INITIUM trial (first-line treatment of patients with unresectable or metastatic malignant melanoma), Ultimovacs has reinstated its commitment to press on with its clinical development of its cancer vaccine, UV1, across other target indications. The principal near-term focus will be on the anticipated results of Phase II FOCUS (head and neck cancer) and DOVACC (ovarian cancer) trials in Q324 and H125, respectively, and will inform its subsequent strategic direc...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.